ES2528441T3 - Hetarilaminonaftiridinas - Google Patents

Hetarilaminonaftiridinas Download PDF

Info

Publication number
ES2528441T3
ES2528441T3 ES11700994.4T ES11700994T ES2528441T3 ES 2528441 T3 ES2528441 T3 ES 2528441T3 ES 11700994 T ES11700994 T ES 11700994T ES 2528441 T3 ES2528441 T3 ES 2528441T3
Authority
ES
Spain
Prior art keywords
alq
nyy
indicates
atoms
het3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11700994.4T
Other languages
English (en)
Inventor
Alfred Jonczyk
Dieter Dorsch
Frank Zenke
Christiane Amendt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Application granted granted Critical
Publication of ES2528441T3 publication Critical patent/ES2528441T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Compuesto de fórmula (I)**Fórmula** donde W1, W5, W6 indican independientemente entre sí N o CH; W2 indica N o CR6; W3 indica N o CR5; con la condición de que al menos uno de W1, W2, W3, W5 o W6 indique N; X indica NR1, Alq, O o S R1 indica H, A o Cic; R5 indica H, A, Hal, OY, CN, -Alq-OY, COOY, -CO-NYY, SA, SO2A, NYY, -OAlq-OY, -OAlq-NYY, -OAlq-NYCOOY, -OAlq-Het3, NO2, -NH-Alq-COOY, -NH-CO-Alq-OY, -NH-CO-Alq-OCOY, -NH-CO-Alq-NYY, -NH-CO-NYY, - NH-CO-Het3, -NY-COOY, -NY-SO2Y, -NH-SO2-NYY, -NH-Het2, -NH-R2, -NY-CO-R2, -NY-CO-NY-R2, -NY-COO-R2, -NY-SO2-R2, -NY-SO2-NY-R2, -OAr, -NY-Ar, -OHet1, NY-Het1, -CO-NYY-NYY, -CO-Het3 o -CO-NH-Alq-Het3; R1, R5 juntos también indican -CH>=CH-, -C(Y)>=N-, -N>=C(Y)-, -C(COY)>=N-, -C(CO-R2)>=N-, -CO-NH-, -NH-CO-, -SO2- NH-, -NH-SO2-, >=CH-NH-CO-, -CH-N(Alq-Het3)-CO-, -CH>=C(NO2)- o -CH>=C(Hal)-; R6 indica H, A, Hal, OY, CN, -Alq-OY, COOY, -CO-NYY, NYY, -NY-COOY, -NH-Alq-NYY, -NH-COA, -NH-COAlq- NYY, -NH-Het2, Het3, -OAr, -NY-Ar, -OHet1, NY-Het1, Het1, -NH-SO2Y, -NH-Cic, -NH-Het3, -NH-Alq-Het3, -NHAlq- OY, -NH-CO-NYY, -NH-CO-Het3, -CO-NH-Het3, -NH-CO-Alq-OY, -NH-CO-Alq-Het3, -CO-NH-Alq-Het3, -NH-CO20 Alq-NH-COOY o -CO-NH-Alq-NYY; R2 indica un carboarilo monocíclico con 5-8 átomos de C o un heteroarilo monocíclico con 2-7 átomos de C y 1- 4 átomos de N, O y/o S, cada uno de los cuales puede estar sustituido por al menos un sustituyente seleccionado a partir del grupo de A, Hal, CN, NYY, OY, >=O; R3, R4 indican independientemente entre sí H, A, Hal, CN, NYY, OY, -OAlq-NYY, -OAlq-OY; Y indica H o A; A indica alquilo ramificado o no ramificado con 1-10 átomos de C, en el que 1-7 átomos de H pueden estar sustituidos por Hal; Cic indica cicloalquilo con 3-7 átomos de C; en el que 1-4 átomos de H pueden estar sustituidos por otro distinto de A, Hal y/u OY; Alq indica alquileno con 1-6 átomos de C, en el que 1-4 átomos de H pueden estar sustituidos independientemente entre sí por Hal y/o CN; Ar indica un carbociclo saturado, insaturado o aromático, monocíclico o bicíclico con 6-10 átomos de C, que puede estar sustituido por al menos un sustituyente seleccionado a partir del grupo de Het3, A, Hal, OY, COOY, -Alq-OY, -Alq-SO2, -Alq-Het1, -OAlq-Het1, NYY, -CO-NYY, -SO2NYY, CN; Het1 indica un heteroarilo monocíclico con 2-7 átomos de C y 1-4 átomos de N, O y/o S, que puede estar sustituido por al menos un sustituyente seleccionado a partir del grupo de A, Hal, OY, COOY, -Alq- OY, -Alq-SO2, NYY, -CO-NYY, -SO2NYY, CN; Het2 indica un heteroarilo bicíclico con 2-9 átomos de C y 1-4 átomos de N, que puede estar sustituido por al menos un sustituyente seleccionado a partir del grupo de R2, A, Hal, OY, COOY, - Alq-OY, -Alq-SO2, NYY, -CO-NYY, -SO2NYY, CN; Het3 indica un heterociclo monocíclico saturado con 2-7 átomos de C y 1-4 átomos de N, O y/o S, que puede estar sustituido por al menos un sustituyente seleccionado a partir del grupo de A, Hal, OY, COOY, -Alq- OY, -Alq-SO2, NYY, -CO-NYY, -SO2NYY, CN; y Hal indica F, Cl, Br o I; y/o las sales fisiológicamente aceptables del mismo.
ES11700994.4T 2010-02-22 2011-01-10 Hetarilaminonaftiridinas Active ES2528441T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10001758 2010-02-22
EP10001758 2010-02-22
PCT/EP2011/000054 WO2011101069A2 (en) 2010-02-22 2011-01-10 Hetarylaminonaphthyridines

Publications (1)

Publication Number Publication Date
ES2528441T3 true ES2528441T3 (es) 2015-02-10

Family

ID=43726535

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11700994.4T Active ES2528441T3 (es) 2010-02-22 2011-01-10 Hetarilaminonaftiridinas

Country Status (15)

Country Link
US (1) US8815893B2 (es)
EP (1) EP2539336B1 (es)
JP (1) JP6151919B2 (es)
KR (1) KR20130036201A (es)
CN (1) CN103097381B (es)
AU (1) AU2011217561B2 (es)
BR (1) BR112012019561A2 (es)
CA (1) CA2790613C (es)
EA (1) EA022064B1 (es)
ES (1) ES2528441T3 (es)
IL (1) IL221221A0 (es)
MX (1) MX2012009475A (es)
SG (1) SG183233A1 (es)
WO (1) WO2011101069A2 (es)
ZA (1) ZA201207133B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5675850B2 (ja) * 2010-02-05 2015-02-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ヘタリール−［１，８］ナフチリジン誘導体
ES2792799T3 (es) * 2010-06-28 2020-11-12 Merck Patent Gmbh [1,8]naftiridinas 2,4-diaril-sustituidas como inhibidores de quinasas para su uso contra el cáncer
RU2665462C2 (ru) 2012-06-27 2018-08-30 Ф. Хоффманн-Ля Рош Аг Соединения 5-азаиндазола и способы их применения
ES2813875T3 (es) 2014-01-01 2021-03-25 Medivation Tech Llc Compuestos y procedimientos de uso
WO2016197027A1 (en) 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
SG11201807834WA (en) 2016-03-16 2018-10-30 Kura Oncology Inc Bridged bicyclic inhibitors of menin-mll and methods of use
JP6919977B2 (ja) 2016-03-16 2021-08-18 クラ オンコロジー，インク． メニン−ｍｌｌの置換された阻害剤及びその使用方法
CA3033752C (en) * 2016-08-15 2022-05-31 Purdue Research Foundation 4-substituted aminoisoquinoline derivatives
EP3601249A4 (en) 2017-03-24 2020-12-16 Kura Oncology, Inc. METHODS OF TREATMENT OF MALIGNANT HEMOPATHIES AND EWING'S SARCOMA
WO2018226976A1 (en) 2017-06-08 2018-12-13 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
US11649251B2 (en) 2017-09-20 2023-05-16 Kura Oncology, Inc. Substituted inhibitors of menin-MLL and methods of use
US20230090552A1 (en) 2020-01-08 2023-03-23 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
WO2022150415A1 (en) * 2021-01-06 2022-07-14 The Penn State Research Foundation Methods and materials for treating hair loss

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994367A (en) * 1997-03-07 1999-11-30 The University Of North Carolina At Chapel Hill Method for treating tumors using 2-aryl-naphthyridin-4-ones
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
WO2000061186A1 (en) 1999-04-08 2000-10-19 Arch Development Corporation Use of anti-vegf antibody to enhance radiation in cancer therapy
AU2004297241A1 (en) * 2003-12-09 2005-06-23 Vertex Pharmaceuticals Incorporated Naphthyridine derivatives and their use as modulators of muscarinic receptors
MXPA06008157A (es) * 2003-12-24 2007-09-07 Johnson & Johnson Tratamiento de gliomas malignos con inhibidores de factor de crecimiento transformante-beta.
US20080107623A1 (en) * 2006-11-01 2008-05-08 Bristol-Myers Squibb Company Inhibitors of Hepatitis C Virus
JP4751856B2 (ja) 2007-07-03 2011-08-17 本田技研工業株式会社 車体側部構造
DE102007049451A1 (de) 2007-10-16 2009-04-23 Merck Patent Gmbh 5-Cyano-thienopyridine
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
DE102008017853A1 (de) 2008-04-09 2009-10-15 Merck Patent Gmbh Thienopyrimidine
JP5507543B2 (ja) 2008-04-29 2014-05-28 ノバルティス アーゲー アクチビン様受容体キナーゼ（ａｌｋ４またはａｌｋ５）阻害剤としてのイミダゾ−ピリジン誘導体
BR112012000660A2 (pt) * 2009-06-25 2016-11-16 Amgen Inc compostos heterociclos e seus usos
JP5675850B2 (ja) * 2010-02-05 2015-02-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ヘタリール−［１，８］ナフチリジン誘導体

Also Published As

Publication number Publication date
WO2011101069A2 (en) 2011-08-25
CA2790613A1 (en) 2011-08-25
SG183233A1 (en) 2012-09-27
MX2012009475A (es) 2012-09-12
CN103097381A (zh) 2013-05-08
US20120316166A1 (en) 2012-12-13
KR20130036201A (ko) 2013-04-11
US8815893B2 (en) 2014-08-26
EA022064B1 (ru) 2015-10-30
AU2011217561B2 (en) 2016-04-21
EP2539336A2 (en) 2013-01-02
CA2790613C (en) 2018-01-02
CN103097381B (zh) 2015-10-07
BR112012019561A2 (pt) 2019-09-24
ZA201207133B (en) 2013-05-29
WO2011101069A3 (en) 2013-02-21
EA201201170A1 (ru) 2013-04-30
AU2011217561A1 (en) 2012-10-11
JP2013520453A (ja) 2013-06-06
EP2539336B1 (en) 2014-10-22
IL221221A0 (en) 2012-10-31
JP6151919B2 (ja) 2017-06-21

Similar Documents

Publication Publication Date Title
ES2528441T3 (es) Hetarilaminonaftiridinas
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
AR065280A1 (es) Agentes antiparasitarios
AR086357A1 (es) Derivados de indazol sustituidos activos como inhibidores de quinasas
ECSP12011684A (es) Inhibidores de los virus flaviviridae.
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
ES2620668T3 (es) Derivados de amidas y sulfonamidas amido espirocíclicas
AR094262A1 (es) Compuestos antivirales para el tratamiento de la hepatitis c
EA201490912A1 (ru) Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2
CO6561783A2 (es) Inhibidores del virus flaviviridae
RS52534B (en) MACROCYCLIC COMPOUNDS OF HINOXALINE AS HCV NS3 PROTEASE INHIBITORS
AR076171A1 (es) Pirazolopirimidinonas 1,6-disustituidas, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento del alzheimer, epilepsia y otras enfermedades del sistema nervioso central.
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
DK2203430T3 (da) N-phenyl-dioxo-hydropyrimidiner anvendelige som inhibitorer for hepatitis C virus (HCV)
ES2422204T3 (es) Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS)
AR078408A1 (es) Derivados de indol como moduladores de los crac
AR082029A1 (es) Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt
CO6220911A2 (es) Composicion herbicida que comprende derivados de isoxazolinma como ingredientes activos
BR112015002153A2 (pt) composto heterocíclico parcialmente saturado contendo nitrogênio
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
ECSP088162A (es) Mezclas pesticidas que comprenden una fenilsemicarbazona
AR079748A1 (es) Arilpirrolidinas plaguicidas
DK1893587T3 (da) Fremgangsmåde til fremstilling af dihydroquinazoliner
AR078270A1 (es) Inhibidores de jak (quinasas janus)
AR075583A1 (es) Derivados de isoxazol/o-piridina con eslabon etilo o etenilo